Login to Your Account



BioMarin's Much-Anticipated GALNS Trial Starts in MPS IVA

By Jennifer Boggs


Wednesday, February 2, 2011
BioMarin Pharmaceutical Inc. launched a pivotal Phase III trial of enzyme replacement therapy (ERT) GALNS (N-acetylgalactosamine 6-sulfatase), the drug widely considered to be a key growth driver for the Novato, Calif.-based biotech.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription